NameUniversità degli Studi di Palermo


TitleBisphosponate -Polyaspartamide conjugates as polymeric carriers for drug targeting to bones
Project id.69
Reference sectorBIOTECHNOLOGY
IP Protection LevelPatent n. 0001403567 of 31/10/2013 - PCT/EP2012/050854 of 20/1/2012
Description of the innovation projectThis invention consists in the production of polymeric carriers obtained by the covalent conjugation of molecules with high bone affinity, such as bisphosphonates, to the poly-N-2-hydroxyethyl-DL-aspartamide. So obtained copolymers (polyaspartamide-bisphosphonates conjugates) showed to be able to accumulate into bone tissues; such as conjugates can act as targeting carriers of other drugs that can be selectively addresses to the bone. Moreover thay can act themself as macromolecular prodrugs, able to carrier bisphosphonates to bone and here to release them in a prolonged way.
State of dev.Patent
Industrial applicationThe present invention describes polymer-conjugated bisphosphonates, wherein the polymer has a supporting structure poly- (hydroxyalkyl) -aspartammidica, capable of accumulasi at bone level and as such can be used as carriers for bone-on heading of other drugs, or conjugated to them incorporated in them, or as macromolecular prodrugs, themselves, are able to accumulate in the bone and to release the same bisphosphonates
Market segmentProduction of polymeric carriers for the administration of drugs useful in the treatment of bone diseases, including bone metastases, such as: antineoplastic agents, steroid anti-inflammatory, antinfiammatori non steroidei, antiangiogenesis factors, growth factors, hormones, bisphosphonates, vitamins, diagnostic agents.
Advantage factorroduction of polymeric carriers for administration of drugs for the treatment of bone diseases, including metastases to bone, such as: Antineoplastic agents, anti-inflammatory steroids and non-steroidal, anti-angiogenic factors, growth factors, hormones, bisphosphonates, vitamins, diagnostic agents.
Commercial challengeThe advantages obtained by the administration of these systems drug/polyaspartamide-bisphosphonates are to increase the bone bioavailability of all drugs that linked to bone targeted carrier, will be able to accumulate into bone and to have herapeutic effect; that will have the aim to decrease the administered dose and to reduce the number of administrations by obtaining strong therapeutic avdantages
Publications and Customer Referecesno publications